MannKind Corporation (MNKD) Stock: Destined To Fall Apart

0

MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation is an incredibly interesting stock. After all, there seems to be no other stock on the market that has the ability to invoke so much emotion among investors. While I was hoping for the best and seeing the positive, even through the first year and a half of the declines, my opinion has changed in a big way. Unfortunately, at this point, it seems like the stock is destined to continue falling until the company implodes. Below we’ll talk about what we’re seeing from the stock today, why I believe that the stock will continue to fall, and what we’ll be watching for with regard to MNKD ahead.





What We’re Seeing From MNKD

As mentioned above, MannKind Corporation hasn’t had the best of times in the market as of late. Unfortunately for the company and its investors, the stock started the day in the red and just continues to fall. At the moment (11:51), MNKD is trading at $0.51 per share after a loss of $0.04 per share (7.16%) thus far today.

Why I Believe The Company Is Doomed To Failure

Before I get too deep into why I believe that MNKD is going to fall apart, it’s important that you know that I was bullish on the stock for some time. At the end of the day, I believe that Afrezza is an incredible product, and I believe that, if promoted properly, it could be the goose that lays the golden egg for the company. I held onto the belief that the company would move forward with strong marketing and would see profits for some time. However, that has changed.

At the end of the day, MannKind has had about 2 years to commercialize Afrezza. In the first year, the company worked with Sanofi, which I believed would fail. So, when the product didn’t sell, I maintained my bullish opinion in hopes that MNKD would soon take control and commercialize properly.











Nonetheless, this year has been all about MNKD with regard to Afrezza. The company ended its relationship with Sanofi and launched its own commercialization process. Unfortunately, this has not led to anything fruitful. In fact, the company is falling well short of anything that would help it to break even in the long run.

The Bottom Line

The bottom line here is that MannKind has created an incredible product. However, they just don’t seem to have the ability to bring the product to the market in a successful way. As a result, I believe that the stock will only continue to fall ahead. Nonetheless, anything can happen. For clues as to where MNKD is headed, I’ll be keeping a close eye on sales reports. As the story develops, I’ll be sure to bring you the news.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

LEAVE A REPLY

Please enter your comment!
Please enter your name here